MS Centers Operate Under Unique Administrative Pressure
Multiple sclerosis centers occupy a distinct place in neurology: they manage patients with a lifelong, variable disease trajectory using some of the most expensive and logistically complex therapies in medicine. A patient on ocrelizumab (Ocrevus) requires infusion scheduling every six months, with pre-infusion labs and vital sign checks. A patient on natalizumab (Tysabri) requires monthly infusions alongside JC virus antibody titer monitoring and stratification risk documentation. A patient transitioning to ofatumumab (Kesimpta) requires subcutaneous injection training coordination.
Layered on top of disease-modifying therapy (DMT) logistics are serial MRI surveillance, EDSS documentation at each visit, patient navigation for assistance programs, and ongoing insurance authorization management. According to the National MS Society, more than 1 million Americans now live with MS — nearly double the previously estimated prevalence — and MS center patient panels continue to expand faster than clinical staff capacity.
Infusion Therapy Scheduling: Coordinating Across Three Stakeholders
Infusion therapy for MS involves at minimum three parties: the prescribing neurologist, the infusion center (hospital-based or standalone), and the specialty pharmacy. Each has its own scheduling system, prior authorization requirements, and patient preparation protocols. A virtual assistant can serve as the central coordinator for this triad.
For ocrelizumab, the VA tracks the six-month infusion cycle per patient, initiates scheduling 4–6 weeks in advance, confirms pre-infusion bloodwork orders and completion, sends patients preparation instructions (including methylprednisolone premedication protocols), and reconciles infusion center confirmations with the practice EHR. For natalizumab, the VA adds monthly cadence tracking, TOUCH program enrollment maintenance, JC index value updates, and stratification review reminders flagged for physician review.
A 2023 analysis published in the Multiple Sclerosis Journal found that treatment gaps in high-efficacy DMT infusions increased relapse risk by 2.4-fold — underscoring the clinical importance of administrative precision in scheduling.
EDSS Documentation Support
The Expanded Disability Status Scale (EDSS) is the primary outcome measure in MS clinical practice and research, but its documentation places a meaningful burden on clinical staff. Accurate EDSS scoring requires integrating findings from the neurological exam across eight functional systems. While scoring itself is the clinician's responsibility, supporting documentation — functional history, ambulation reports, and assistive device notation — can be gathered by a VA ahead of each visit through patient questionnaires and caregiver interviews.
A VA can send structured pre-visit surveys aligned with EDSS functional domains, compile responses in a format ready for clinician review, and update historical EDSS trends in the patient's chart. This reduces in-room documentation time and supports longitudinal disability tracking for clinical trial screening and insurance appeals.
MRI Surveillance Tracking
MS MRI surveillance protocols typically call for annual or biannual brain and spine imaging, with more frequent imaging during treatment escalation or signs of disease activity. In a panel of several hundred MS patients, tracking individualized surveillance intervals across payers, imaging centers, and scheduling availability is a full-time administrative job.
A virtual assistant can maintain an MRI surveillance registry, send scheduling reminders to patients at the appropriate interval, coordinate with imaging centers for protocol-appropriate sequences (including gadolinium administration documentation), and flag overdue scans for provider review. This prevents the common scenario in which surveillance lapses go unnoticed until a patient presents with new symptoms.
Patient Assistance Program Enrollment
With branded MS DMTs carrying list prices exceeding $80,000–$100,000 per year, patient assistance program (PAP) enrollment is often essential to treatment access. VA can manage the PAP enrollment lifecycle: identifying eligible programs (Genentech's Ocrevus Access Solutions, Biogen's MS Active Source, Novartis's Kesimpta Support), gathering required documentation, completing enrollment forms, tracking approval status, and managing annual re-enrollment.
MS centers looking to scale their administrative capacity can partner with experienced healthcare VAs through Stealth Agents, which provides specialists in high-complexity specialty clinic support.
Sources
- National MS Society. "MS Prevalence in the United States." NationalMSSociety.org, 2023.
- Multiple Sclerosis Journal. "Treatment Gaps in High-Efficacy DMT Infusion and Relapse Risk." MSJ, 2023; 29(3): 412–421.
- Biogen. "MS Active Source Program Overview." Biogen.com, 2024.
- Genentech. "Ocrevus Access Solutions Patient Support." Gene.com, 2024.